International Oncology Network - Cancer & Hematology News
All Blog Posts Tagged 'Cajal' (1)
Imatinib Mesylate After Surgery Dramatically Reduces Risk of Cancer Returning in Patients with Gastrointestinal Stromal Tumors
The U.S. Food and Drug Administration, in late December 2008, approved imatinib mesylate (Glivec®, Novartis AG, Lichtstrasse 35, 4056 Basel, Switzerland and Gleevec®, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, NJ) for the post-surgery treatment of adult patients following complete surgical removal of KIT (CD117)-positive gastrointestinal stromal tumors (GIST).
The tyrosine kinase inhibitor imatinib mesylate is now the only post-surgery treatment… Continue
The tyrosine kinase inhibitor imatinib mesylate is now the only post-surgery treatment… Continue
Added by Peter Hofland, PhD on January 19, 2009 at 6:00pm — No Comments
Latest Blog Posts
Most Popular Blog Posts
Monthly Archives
2013
2012
- December (32)
- November (19)
- October (17)
- September (9)
- August (10)
- July (4)
- June (29)
- May (16)
- April (6)
- March (4)
- February (21)
- January (38)
2011
- December (47)
- November (32)
- October (21)
- September (32)
- August (18)
- July (23)
- June (83)
- May (45)
- April (54)
- March (36)
- February (62)
- January (43)
2010
- December (58)
- November (49)
- October (65)
- September (23)
- August (7)
- July (4)
- June (34)
- May (7)
- April (7)
- March (5)
- February (3)
- January (6)
2009
2008
- December (19)
2007
- April (1)
2005
2004
- September (1)
2001
- November (1)
ADVERTISEMENT
Bookmark / Share
Join the Conversation!
© 2013 Created by Peter Hofland, PhD.
